EGFR and non-small cell lung carcinoma: In the phase 1B dose escalation part of the study, tolerance in the absence of pharmacokinetic interactions and the activity of gefitinib plus olaparib were confirmed in 22 patients with EGFR-mutant NSCLC. The recommended phase 2 dose was 250 mg of gefitinib once daily plus 200 mg of olaparib three times daily